Healthcare Sep 02, 2021 02:26 PM (GMT+8) · EqualOcean
XinDa bio will be the exclusive partner to win the right to develop and commercialize GFH925 in China (including Chinese mainland, Hongkong, Macao and Taiwan) and has the right to choose global development and commercialization rights as a candidate drug GFH925 KRAS. Cinda bio will pay JinFang pharmaceutical a down payment of US $22 million after signing the agreement. If Cinda biology exercises the option of global rights and interests, JinFang medicine will also receive a cumulative global development support fee of no more than US $50 million. Depending on the progress of reaching several global development, registration and sales milestones, JinFang medicine will be eligible for milestone payments from Cinda biology, which will not exceed US $240 million in aggregate, as well as gradient royalties based on the annual net sales of gfh925 in China and around the world.

This text is a result of machine translation.

Related companies：